Zhejiang Genfleet Therapeutics Co. Ltd.

Research activity is centered on non-small cell lung cancer, with emphasis on previously untreated advanced NSCLC and disease settings defined by KRAS G12C mutation. The sponsor’s clinical portfolio reflects a focused interest in targeted approaches for advanced lung malignancies.

• Advanced NSCLC
• KRAS G12C-mutant lung cancer
• Previously untreated disease

Clinical research in this area is directed toward patients with metastatic and unresectable lung cancer requiring mutation-specific treatment strategies.